Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in pediatric patients with sickle cell disease.
about
Biologic complexity in sickle cell disease: implications for developing targeted therapeuticsDrugs for preventing red blood cell dehydration in people with sickle cell diseaseInhaled nitric oxide for treating pain crises in people with sickle cell diseaseDrugs for preventing red blood cell dehydration in people with sickle cell diseaseDrugs for preventing red blood cell dehydration in people with sickle cell disease2015 Clinical trials update in sickle cell anemiaAdenosine A2A receptors induced on iNKT and NK cells reduce pulmonary inflammation and injury in mice with sickle cell disease.NKT cells mediate pulmonary inflammation and dysfunction in murine sickle cell disease through production of IFN-gamma and CXCR3 chemokines.Extrapulmonary effects of inhaled nitric oxide: role of reversible S-nitrosylation of erythrocytic hemoglobin.Pulmonary complications of sickle cell disease.Molecular mechanisms underlying synergistic adhesion of sickle red blood cells by hypoxia and low nitric oxide bioavailability.A pilot study of eptifibatide for treatment of acute pain episodes in sickle cell disease.Glycosylation inhibitors efficiently inhibit P-selectin-mediated cell adhesion to endothelial cellsAcute chest syndrome: sickle cell disease.Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes.Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy.Newer aspects of the pathophysiology of sickle cell disease vaso-occlusion.Postdischarge pain, functional limitations and impact on caregivers of children with sickle cell disease treated for painful events.Inhaled nitric oxide for the adjunctive therapy of severe malaria: protocol for a randomized controlled trial.Pharmacotherapy in sickle cell disease--state of the art and future prospectsNitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trialRedox-dependent impairment of vascular function in sickle cell disease.Socio-environmental exposures and health outcomes among persons with sickle cell diseaseSickle cell disease and nitric oxide: a paradigm shift?The genomics of new drugs in sickle cell disease.Sickle cell disease: role of reactive oxygen and nitrogen metabolites.Advances in clinical research in sickle cell disease.Novel small molecule therapeutics for sickle cell disease: nitric oxide, carbon monoxide, nitrite, and apolipoprotein A-I.Investigational drugs in sickle cell anemia.Sickle cell anemia and vascular dysfunction: the nitric oxide connection.Novel therapies targeting the endothelium in sickle cell disease.Hemolysis-induced acute kidney injury following cardiac surgery: a case report and review of the literature.Updated role of nitric oxide in disorders of erythrocyte function.Psychosocial and pharmacological management of pain in pediatric sickle cell disease.Nitric oxide for the adjunctive treatment of severe malaria: hypothesis and rationale.Inhaled nitric oxide for acute chest syndrome in adult sickle cell patients: a randomized controlled study.The associations between air quality and the number of hospital admissions for acute pain and sickle-cell disease in an urban environment.Unlocking the binding and reaction mechanism of hydroxyurea substrates as biological nitric oxide donorsPathophisiology of sickle cell disease and new drugs for the treatment.Circulating platelet and erythrocyte microparticles in young children and adolescents with sickle cell disease: Relation to cardiovascular complications.
P2860
Q21284789-BCD81174-4AB5-4529-935A-4CAC020B64B2Q24186046-DB348164-4E53-43E4-9B46-8037C0318C83Q24186749-EFC40B85-7FB0-45FD-9733-3912D64C19F3Q24202032-37C3A22A-9F32-48B4-8604-BD9FE5B9CD79Q24240777-F6BD825D-06CA-42C1-80AB-1A3BBB6C04B5Q28086979-1666ED1E-4220-4412-BF1A-18F63383C7EBQ30429393-885B9D63-9802-4858-84A6-7E4F74B186B3Q30435470-0B0A0CD2-C9AC-4B0B-B58E-5CD6BFFE76C7Q30440013-AF131577-55ED-44AF-A0CE-7275B58F13FCQ30515769-2A9985F1-8C2C-48B3-823D-AC29103B781BQ30574476-471B566E-B960-48AD-870C-3DDD4E821ACDQ33409969-4FDEFCD6-F9AC-468B-AE5A-DF73FAE6627FQ33778831-C5A0DE31-AB6A-413E-AA58-F3ADBF3D5E41Q34187526-A2401951-EE3E-4FD3-9801-A653CC1DF548Q34579250-93C5E279-3FAF-478F-B15F-CCF7CD03C92CQ34898802-20489DD5-100D-4A82-965F-0910A4B5D43CQ34941213-9F346C73-2EDB-4544-89DF-E0504DFABC46Q35055191-4D67D541-10F6-416F-B88B-773A0E82DCC3Q35150645-D40D633C-340D-482B-8A3F-4481B11DBC53Q35220342-D8324B27-F5E4-4E1F-82E0-3F20858AD335Q36112390-4E265E1B-7076-4D68-9E8C-7546A13E0EC6Q36274222-DC65F0E4-E262-4A07-936A-80ACE3361497Q36338160-4AEE5B45-5C82-469C-AE01-9A5F0D170B3BQ36381179-A4907B36-BF4A-4EDF-AAE7-428C2817D5F1Q36596719-0687CB32-4DFC-4849-85A3-70291FB6664EQ36889232-63EA3EAF-454F-4318-97EB-7D746B2D90A5Q37110303-C43D2ACF-93DA-42C1-8626-6A6B23F99504Q37346719-361EC845-817B-4211-8D2D-D2BC74979641Q37603352-153E107D-F0C7-4898-A084-331C98AAC6D5Q37767680-37317620-78C5-4BD3-889B-43D1E069B442Q37930655-755A610B-1041-4DF9-B4A5-7123ACC748ACQ38003729-BBD37FF5-95C7-434B-89AF-2643E4F72FB1Q38093677-A5D7C803-33FB-45E7-9A1F-9026753EE4CCQ38200831-9DC26965-58BF-40B9-B1A7-7305C3B781E5Q38262285-B9FB22D6-0338-4D05-AF79-6CABA57135B1Q38957306-836E03DC-B27B-4A11-A9A1-FD50240B6A88Q39788896-256DDF23-3DB0-44A2-8BDC-FD8FD985E116Q41763205-7B624E2D-B911-41DE-A0B2-623EF2C43B8BQ41777376-A420E85C-71F7-46C7-B7E4-FB15209D2E72Q46344026-076F38B4-D281-4B72-A6F3-F906E66894A9
P2860
Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in pediatric patients with sickle cell disease.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Preliminary assessment of inha ...... ents with sickle cell disease.
@en
Preliminary assessment of inha ...... ents with sickle cell disease.
@nl
type
label
Preliminary assessment of inha ...... ents with sickle cell disease.
@en
Preliminary assessment of inha ...... ents with sickle cell disease.
@nl
prefLabel
Preliminary assessment of inha ...... ents with sickle cell disease.
@en
Preliminary assessment of inha ...... ents with sickle cell disease.
@nl
P2093
P356
P1476
Preliminary assessment of inha ...... ents with sickle cell disease.
@en
P2093
Andrew B Cooper
Carlo Brugnara
Christine A Botelho
Debra L Weiner
Patricia L Hibberd
Peter Betit
P304
P356
10.1001/JAMA.289.9.1136
P407
P577
2003-03-01T00:00:00Z